Onartuzumab

From WikiMD.org
Jump to navigation Jump to search

Onartuzumab

Onartuzumab (pronunciation: on-ar-tuz-u-mab) is a monoclonal antibody designed for the treatment of cancer. It is a therapeutic agent that targets the MET receptor, a protein often found in high levels on the surface of cancer cells.

Etymology

The name "Onartuzumab" is derived from the International Nonproprietary Names (INNs), where "onartu-" refers to the oncology target, "-zu-" indicates humanized antibody, and "-mab" is the suffix for monoclonal antibodies.

Mechanism of Action

Onartuzumab works by binding to the MET receptor on the surface of cancer cells, thereby inhibiting the receptor's activity. This can lead to a decrease in cancer cell growth and proliferation.

Clinical Trials

Onartuzumab has been studied in several clinical trials, including those for non-small cell lung cancer (NSCLC) and gastric cancer. However, the results have been mixed, and the drug is not currently approved for use.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski